In this cross-sectional universal genetic testing study of women with newly diagnosed invasive breast cancer, 7.3% had a GPV in a BCSG, with 5.3% of patients testing positive for B1B2P2. Of those testing positive for BRCA1/2 or PALB2, one-third were eligible for PARP inhibitors. The gene discussed is BRCA1; the disease is invasive breast carcinoma.